| Hans-Günter Meyer-Thompson | Buprenorphin
Probuphine® Implant for Opioid Dependence Featured at 2016 International Society of Addiction Medicine Meeting
PRINCETON, N.J. and SOUTH SAN FRANCISCO, Calif. and MONTREAL. Braeburn Pharmaceuticals, Inc. and Titan Pharmaceuticals, Inc. today announced that three Probuphine presentations were featured at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week. Probuphine, a subdermal implant, is the first commercially available six-month maintenance treatment for opioid dependence. (PRNewswire, 28.10.2ß16)